Publications by authors named "Douglas Logan"

Claim this Profile
I
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.
Amanda K Rudman Spergel, Ivan T Lee, Kindra Koslovsky, Kristi Schaefers, Andrei Avanesov, Douglas K Logan

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?
Deepak L Bhatt, Tilo Grosser, Jing-Fei Dong, Douglas Logan, Walter Jeske

J Am Coll Cardiol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
Deepak L Bhatt, Tilo Grosser, Jing-Fei Dong, Douglas Logan, Walter Jeske

J Am Coll Cardiol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
Eric G Vajda, Douglas Logan, Kenneth Lasseter, Danielle Armas, Diane J Plotkin

Diabetes Obes Metab· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
Robert R Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey

J Diabetes Complications· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Robert R Henry, Julio Rosenstock, Douglas K Logan, Thomas R Alessi, Kenneth Luskey

Diabetes Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Paul A Gurbel, Kevin P Bliden, Douglas K Logan, Dean J Kereiakes, Kenneth C Lasseter

J Am Coll Cardiol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Robert R Henry, Douglas Logan, Thomas Alessi, Michelle A Baron

Clin Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Matthew J Price, James S Walder, Brian A Baker, Darell E Heiselman, Joseph A Jakubowski, Douglas K Logan

J Am Coll Cardiol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Evan A Stein, Scott Mellis, George D Yancopoulos, Neil Stahl, Douglas Logan

N Engl J Med· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis